Umoja Biopharma

We look forward to our first presentation of VivoVec's in vivo autoimmunity applications at the upcoming ACR Convergence 2024! Please join Maura Parker in Washington D.C. as she highlights our early in vitro and in vivo data for autoimmunity in November. Full details: https://lnkd.in/g6CMgWv6

Please join us at next week's CAR-TCR Summit in Boston as Ryan Crisman, our Co-founder and CTO, presents on our foundational operations investments and joins an industry panel on the emerging promise of the in vivo space. Full details here: https://lnkd.in/gUD-x7dE

Our co-founder and CTO Ryan Crisman will be presenting at tomorrow's Wedbush Securities PacGrow Healthcare Conference on an industry panel titled "Breaking Out of Cell Therapy," covering the promising future of off-the-shelf cell therapy approaches including our own here at Umoja Biopharma. If you are attending the Wedbush conference, please join us live at 9:30am ET for the panel discussion.

We are thrilled to share that the FDA has cleared our Investigational New Drug (IND) application for UB-VV111, an in-situ generated CAR T-cell therapy for hematologic malignancies. We expect to treat our first patient by the end of year in our Phase 1 study, named INVICTA-1. UB-VV111 represents a significant advancement in off-the-shelf therapies, being the first in vivo CAR T cell therapy to be evaluated in the clinic here in the U.S. Learn more in our press release:

At Umoja, we aim to continuously create an environment where everyone can feel included and represented, and bring their full selves to our lofty goals of transforming the field of immunotherapy. During Pride Month this year, we honored and celebrated our LGBTQIA+ colleagues and allies along with their contributions to advance our science. Thank you to our YOUmoja committee and both our sites in Colorado and Washington for organizing such great events like this year's Pride celebrations! 🌈 🧪 #PrideMonth #LoveIsLove #LifeSciences

We are honored to announce the publication of the first successful in vivo CAR T-cell non-human primate data in Blood, the flagship journal of American Society of Hematology, stemming from our pre-clinical investigations of our proprietary VivoVec™ particles. Learn more about this continued validation of our platform and how our science at Umoja could be laying the groundwork for a paradigm shift in the field of CAR T-cell therapies:

We are honored to announce the publication of the first successful in vivo CAR T-cell non-human primate data in Blood, the flagship journal of American Society of Hematology, stemming from our pre-clinical investigations of our proprietary VivoVec™ particles. Learn more about this continued validation of our platform and how our science at Umoja could be laying the groundwork for a paradigm shift in the field of CAR T-cell therapies:

In our latest blog post, our CEO, Andy Scharenberg reflects on his experience as a panelist at #SXSW2024 and details his goal of advancing practice-changing #CellTherapies. Read more about his panel, “From Adversary to Ally: Reimagining Viruses As Medicines” here: https://lnkd.in/g9J8RZFB #MedicinesGoViral

Here at Umoja, our world-class team is united by our shared goal of unlocking the true potential of #CART cell therapies. We're recognizing #WorldBloodCancerDay by sharing our commitment to extending the benefits of #immunotherapy to every patient bearing the burden of #cancer.

We're proud to announce that Umoja scientist Ashley Yingst abstract on Synthetic Receptor Enabled Differentiation (ShRED) received the ISCT, International Society for Cell & Gene Therapy Stem Cell Engineering Abstract Award. This recognition reflects Umoja’s commitment to advancing "off-the-shelf" #Immunotherapies. More on this prestigious award: https://bit.ly/3y8QPak